Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick Vermersch

Showing results (211-220 of 250) with videos related to

Pageof 25
Sort By:
Journal of the Neurological Sciences|January 22, 2026
Directions for advancing prognostic assessments in multiple sclerosis: Qualitative Insights from MS specialist InterviewsSofie Aerts, Lotte Geys, Deborah Severijns, et al.
Frontiers in Immunology|September 3, 2024
A future of AI-driven personalized care for people with multiple sclerosisJelle Praet, Lina Anderhalten, Giancarlo Comi, et al.
Advances in Therapy|September 6, 2019
Joint Healthcare Professional and Patient Development of Communication Tools to Improve the Standard of MS CareCelia Oreja-Guevara, Stanca Potra, Birgit Bauer, et al.
Neurology and Therapy|June 24, 2021
Confirmed 6-Month Disability Improvement and Worsening Correlate with Long-term Disability Outcomes in Alemtuzumab-Treated Patients with Multiple Sclerosis: Post Hoc Analysis of the CARE-MS StudiesSamuel F Hunter, Rany A Aburashed, Raed Alroughani, et al.
Journal of Neurology|May 31, 2022
Siponimod vs placebo in active secondary progressive multiple sclerosis: a post hoc analysis from the phase 3 EXPAND studyRalf Gold, Daniela Piani-Meier, Ludwig Kappos, et al.
Advances in Therapy|October 9, 2023
Summary of Research: Collaboration Between Healthcare Professionals and People with Multiple Sclerosis to Develop Communication Tools to Improve the Standard of Multiple Sclerosis CareCelia Oreja-Guevara, Stanca Potra, Birgit Bauer, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|April 27, 2021
Serum Neurofilament Levels and PML Risk in Patients With Multiple Sclerosis Treated With NatalizumabNicolás Fissolo, Beatrice Pignolet, Jordi Rio, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 26, 2019
Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studiesGiancarlo Comi, Raed Alroughani, Aaron L Boster, et al.
Bulletin Du Cancer|November 28, 2017
[Indications and follow-up for autologous hematopoietic stem cell transplantation in autoimmune and autoinflammatory diseases: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)]Grégory Pugnet, Christina Castilla-Llorente, Mathieu Puyade, et al.
Multiple Sclerosis and Related Disorders|December 5, 2020
Multiple Sclerosis Data Alliance - A global multi-stakeholder collaboration to scale-up real world data researchLiesbet M Peeters, Tina Parciak, Dipak Kalra, et al.
Pageof 25

Showing results (211-220 of 250) with videos related to

Sort By:
Pageof 25
Journal of the Neurological Sciences|January 22, 2026
Directions for advancing prognostic assessments in multiple sclerosis: Qualitative Insights from MS specialist InterviewsSofie Aerts, Lotte Geys, Deborah Severijns, et al.
Frontiers in Immunology|September 3, 2024
A future of AI-driven personalized care for people with multiple sclerosisJelle Praet, Lina Anderhalten, Giancarlo Comi, et al.
Advances in Therapy|September 6, 2019
Joint Healthcare Professional and Patient Development of Communication Tools to Improve the Standard of MS CareCelia Oreja-Guevara, Stanca Potra, Birgit Bauer, et al.
Neurology and Therapy|June 24, 2021
Confirmed 6-Month Disability Improvement and Worsening Correlate with Long-term Disability Outcomes in Alemtuzumab-Treated Patients with Multiple Sclerosis: Post Hoc Analysis of the CARE-MS StudiesSamuel F Hunter, Rany A Aburashed, Raed Alroughani, et al.
Journal of Neurology|May 31, 2022
Siponimod vs placebo in active secondary progressive multiple sclerosis: a post hoc analysis from the phase 3 EXPAND studyRalf Gold, Daniela Piani-Meier, Ludwig Kappos, et al.
Advances in Therapy|October 9, 2023
Summary of Research: Collaboration Between Healthcare Professionals and People with Multiple Sclerosis to Develop Communication Tools to Improve the Standard of Multiple Sclerosis CareCelia Oreja-Guevara, Stanca Potra, Birgit Bauer, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|April 27, 2021
Serum Neurofilament Levels and PML Risk in Patients With Multiple Sclerosis Treated With NatalizumabNicolás Fissolo, Beatrice Pignolet, Jordi Rio, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 26, 2019
Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studiesGiancarlo Comi, Raed Alroughani, Aaron L Boster, et al.
Bulletin Du Cancer|November 28, 2017
[Indications and follow-up for autologous hematopoietic stem cell transplantation in autoimmune and autoinflammatory diseases: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)]Grégory Pugnet, Christina Castilla-Llorente, Mathieu Puyade, et al.
Multiple Sclerosis and Related Disorders|December 5, 2020
Multiple Sclerosis Data Alliance - A global multi-stakeholder collaboration to scale-up real world data researchLiesbet M Peeters, Tina Parciak, Dipak Kalra, et al.
Pageof 25